Ground Truths

Jennifer Gunter & Eric Topol: Discuss Women’s Health and Recent Changes by FDA for MHT

13 snips
Nov 28, 2025
In this discussion, Dr. Jennifer Gunter, a leading gynecologist and women's health advocate, teams up with Eric Topol to dive into the recent FDA changes regarding menopausal hormone therapy (MHT). They tackle complex issues like the misconceptions around MHT’s cognitive benefits and the impact of various hormone delivery methods on risks. Gunter critiques the wellness industry's marketing tactics and emphasizes the need for proper research funding in women's health. Their conversation highlights the intricate balance between symptom relief and informed care.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Healthy-User Bias Skews Observational MHT Data

  • Much observational evidence of MHT benefit reflects healthy-user bias and socioeconomic confounding.
  • Dr. Jennifer Gunter highlights Denmark data showing pre- and post-WHI differences in mortality associations.
ADVICE

Use MHT For High Osteoporosis Risk

  • Use MHT for fracture prevention when an individual has high osteoporosis risk.
  • Assess baseline fracture risk before prescribing and tailor therapy accordingly.
ADVICE

Prefer Transdermal When Clot Risk Exists

  • Avoid oral estrogen in patients with clotting risk due to 2–4x increased VTE risk.
  • Prefer transdermal estrogen when clot risk is a concern, noting evidence is observational.
Get the Snipd Podcast app to discover more snips from this episode
Get the app